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OBJECTIVE: Current clinical consensus supports an initial
Helicobacter pylori (HP) “test and treat” approach when
compared to immediate endoscopy for patients with sus-
pected peptic ulcer disease. Alternative diagnostic ap-
proaches that incorporate upper GI radiography (UGI) have
not been previously evaluated. We sought to determine the
cost effectiveness of UGI compared to a HP test and treat
strategy, incorporating recent data addressing the reduced
prevalence of HP, lower cost of diagnostic interventions,
and reduced attribution of PUD to HP.
METHODS: Using decision analysis, three diagnostic and
treatment strategies were evaluated: 1)Test and Treat—
initial HP serology, treat patients who test positive with HP
eradication and antiulcer therapy; 2)Initial UGI series—
treat all patients with documented ulcer disease with HP
eradication and antiulcer therapy; and 3)Initial UGI series,
HP serology if ulcer present— treat ulcer and HP based on
diagnostic test results.
RESULTS: The estimated cost per ulcer cured for each strat-
egy were as follows: test and treat, $3,025; initial UGI,
$3,690; and UGI with serology, $3,790. The estimated cost
per patient treatment were: test and treat, $498; initial UGI,
$610; and UGI with serology, $620. When UGI reimburse-
ment was decreased to less than $50, the UGI strategies
yielded a lower cost per patient treated than the test and treat
strategy.
CONCLUSION: At the current level of reimbursement, UGI
should not be considered a cost-effective alternative to the
HP test and treat strategy for the initial evaluation of patients
with suspected peptic ulcer disease. (Am J Gastroenterol
2000;95:651–658. © 2000 by Am. Coll. of Gastroenterol-
ogy)
INTRODUCTION
Upper abdominal pain is a common symptom complex
accounting for an estimated 4–5% of primary care physician
office visits per year (1). Clinical approaches to the man-
agement of dyspepsia rely heavily upon history and impres-
sion, although a poor correlation exists between patient
symptoms and objective findings on diagnostic testing.
Thus, the optimal clinical algorithm remains elusive. Be-
cause of its prevalence, defining a diagnostic and treatment
strategy for individuals with dyspepsia that is clinically
effective and economically acceptable is imperative. This is
particularly timely, given concerns regarding the high cost
of endoscopy and apprehension over the inappropriate use
of eradication therapy for individuals infected withHelico-
bacter pylori (HP) infection without a diagnosis of peptic
ulcer disease (PUD).
Dyspeptic symptoms may be caused by a number of
underlying etiologies, including PUD, gastroesophageal re-
flux, nonulcer dyspepsia, and rarely, malignancy. There is
strong consensus that patients presenting with dyspepsia and
“alarm” symptoms (e.g., weight loss, dysphagia, early sati-
ety, anemia) should be promptly evaluated with endoscopy
(2). The approach to the great majority of symptomatic
individuals who present without alarm symptoms is less
clear. As many underlying diagnoses have overlapping
symptoms, it is difficult, without invasive testing, to distin-
guish among them (3).
In a 1993 evaluation of open-access endoscopy units,
20% of dyspeptic patients were found to have active PUD
unrelated to NSAID use (4). The prevalence of HP infection
in those individuals with documented PUD was 90%. How-
ever, recent evidence suggests that the incidence of HP
infection in individuals with and without PUD is declining,
likely because of the declining infection rate and widespread
use of antibiotic therapy (5).
For patients with suspected PUD, decision analytic mod-
els support initial noninvasive diagnostic strategies as the
preferred approach when compared to immediate endoscopy
(6, 7). HP serology testing (with endoscopy reserved for
treatment failures) is the preferred noninvasive approach. In
addition to the cost-effectiveness advantage of the test and
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treat approach when compared to endoscopy, the availabil-
ity and convenience of serological testing make this strategy
attractive. However, in the face of declining HP prevalence,
the positive predictive value of serological testing declines,
raising the issue of whether a objective diagnosis of PUD
before eradication therapy is warranted on clinical and eco-
nomic grounds.
Cost containment efforts and the desire to prescribe HP
eradication only to those patients with PUD necessitate the
evaluation of UGI as the initial invasive diagnostic test. The
ability of UGI to document the presence or absence of PUD
may confer a clinical and cost-effective advantage over the
test and treat approach by focusing eradication therapy on
those individuals most likely to benefit from HP cure. The
widespread availability, patient convenience, and relative
decreased cost of UGI, as compared to EGD, may make it
an appropriate initial diagnostic alternative for patients with
suspected PUD. For these and other reasons, UGI use re-
mains high in clinical practice (8).
The performance characteristics of UGI and endoscopy
have been compared in randomized prospective studies in-
volving symptomatic patients (9–11). UGI has been shown
to accurately identify structural lesions such as stricture,
carcinoma, and outlet obstruction, but is less reliable than
endoscopy for mucosal lesions such as PUD. The sensitivity
of UGI is reported for the diagnosis of PUD over a wide
range (0.5–0.9). The shortcomings of UGI include the in-
ability to obtain a tissue diagnosis, which may be used to
document active HP infection.
MATERIALS AND METHODS
We used decision analysis to estimate the clinical and eco-
nomic impact of three diagnostic and treatment strategies in
a cohort of patients with uncomplicated ulcer-like dyspep-
sia. Details of the decision analytic model have been pub-
lished elsewhere (6). Strategies evaluated included: 1)Test
and treat—initial HP serology, treat HP positives with erad-
ication therapy and ulcer healing therapy (no ulcer test); 2)
Initial upper GI series—treat all patients with documented
ulcers with ulcer healing and HP eradication therapy (no HP
test); and 3)Initial upper GI series with HP serology if ulcer
present—treat based on diagnostic test results.
Patients were followed in the simulation for up to 1 yr,
and costs related to diagnostic testing and health care use
were determined over that time. This time frame obviated
the requirement for discounting of costs.
The model captured resource use, such as physician vis-
its, pharmaceutical use, procedures, and hospitalizations.
Direct medical expenditures were calculated from these
data. After the initial management encounter, patients
moved among different states of health determined by the
likelihood of particular clinical events and the effect of
certain medical interventions on the natural history of peptic
ulcer disease. Each patient was evaluated at 6-wk intervals
for 1 yr for the presence or absence of three clinical condi-
tions (i.e., recurrent symptoms, HP infection, and active
ulcer disease) upon which all further interactions with the
medical care system were based.
Study Population
A cohort of 1000 patients with uncomplicated ulcer-like
dyspepsia who were not taking nonsteroidal anti-inflamma-
tory agents (NSAIDs) was entered into the simulation for
the analysis. The assumption was made that no prior eval-
uation for HP had been performed and, likewise, no prior
history of PUD documented.
Initial Diagnostic and Therapeutic Interventions
TEST AND TREAT STRATEGY. All patients in this
group underwent qualitative serological testing for HP.
Those with evidence of previous or current infection (test
positive) received eradication therapy consisting of antise-
cretory agents and antibiotics for 2 wk and a subsequent 2
wk of antisecretory therapy. Patients who had a negative
serology were prescribed standard dose antisecretory ther-
apy for one month. Regardless of HP test results, patients
who continued to have symptoms or relapsed after comple-
tion of therapy had endoscopy performed.
INITIAL UGI. UGI radiography was performed in the stan-
dard fashion. If an ulcer was identified, HP infection was
presumed without testing. Patients with PUD received 2 wk
of HP eradication therapy (antibiotics and ulcer healing
doses of antisecretory therapy) and an additional 2 wk of
antisecretory therapy. If UGI was negative for PUD, pa-
tients were prescribed a 4-wk course of standard dose anti-
secretory therapy. Again, patients who continued to have
symptoms or relapsed after completion of therapy under-
went endoscopy.
INITIAL UGI WITH HP SEROLOGY IF ULCER
PRESENT. UGIradiography was performed and patients
underwent HP testing only if an ulcer was identified. In the
PUD positive patients in whom HP serology was positive, 2
wk of eradication therapy and and additional 2 wk of anti-
secretory therapy was prescribed. If HP serology was neg-
ative and PUD was present, patients received 4 wk of
antisecretory therapy at ulcer healing doses. If no ulcer was
identified, patients were prescribed 4 wk of standard dose
antisecretory therapy. If symptoms were persistent or recur-
rent, patients underwent endoscopy.
In sum, this model designed to evaluate initial diagnostic
testing, treated all patients with antisecretory medications
when a nonulcer source of dyspepsia was identified.
Data Sources
CLINICAL PROBABILITIES. Pertinent clinical data were
obtained from a MEDLINE database search and a review of
peer-reviewed journals not included in the database. Table 1
displays clinical input probabilities used in the simulation
and ranges used in sensitivity analyses.
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EPIDEMIOLOGY. The base case analysis postulated that
50% of the cohort entered into the model was infected with
HP (12, 13). In concordance with studies of open access
endoscopy, 20% of the cohort had active PUD (14–21). The
percentage of patients with active PUD who were infected
with HP was assumed to be 90% (4, 5, 22, 23).
DIAGNOSIS OF HP INFECTION. The qualitative serol-
ogy test was presumed to have 90% sensitivity and 95%
specificity (24, 25). Rapid urease testing (RUT), performed
with endoscopy in persistently symptomatic patients, was
assigned 92% sensitivity and 92% specificity (26, 27).
DIAGNOSIS OF PUD. Endoscopy was presumed to be
100% sensitive and specific for detection of PUD. Optimal
performance characteristics for UGI were obtained from the
literature and assumed 90% sensitivity and 90% specificity
for detection of PUD (9–11). Active ulcer disease was
presumed to be symptomatic.
HP ERADICATION THERAPY. Multiple eradication reg-
imens of varying efficacy, cost, and compliance were eval-
uated. Therapy for eradication of HP was felt to have an
impact on ulcer recurrence but not symptom resolution if
symptoms were unrelated to PUD. HP eradication rates
were estimated at 85% and ulcer healing was estimated at
90% (28–43). Reinfection was assumed not to occur after
eradication (44). After ulcer healing, 10% of ulcer related
symptoms recurred (45). Ulcer recurrence with and without
HP infection were estimated at 2.7% and 0.6% per 100
patient-months, respectively, in the base case analysis (22,
46–55).
For those individuals whose symptoms were not due to
active ulcer disease, symptoms recurred at the rate of 30%
after a course of antisecretory therapy and required a phy-
sician visit (56, 57). These patients then underwent endos-
copy if not previously performed. Once the absence of an
ulcer was documented these patients did not undergo further
diagnostic testing and received symptomatic management
for the remainder of the simulation. The remainder of pa-
tients who did not have symptom recurrence used no further
resources.
Cost Inputs
All diagnostic testing, treatments, and resource use were
included in cost calculation up until the time of endoscopy
identifying the cause of the dyspepsia. After the diagnosis of
PUD was excluded by endoscopy, treatment costs for non-
PUD etiologies of dyspepsia were excluded. Costs of a
follow-up endoscopy and rapid urease test (RUT) after UGI
revealed a gastric ulcer were not included if the patient
remained asymptomatic.
Cost calculations of medical resource use were based
Table 1. Clinical and Cost Inputs
Variable Base Case (Range) Study References
Clinical probability
Active ulcer disease, % 20 (5–30) 4, 14–21
H. pylori infection if ulcer is present, % 90 (60–90) 5, 22, 23
H. pylori infection if no ulcer is present, % 50 (20–60) 12, 13
Ulcer healing rate after antisecretory therapy, % 90 (50–90) 41–43
H. pylori eradication after antibiotic course (includes compliance), % 85 (50–90) 28–40
Recurrent symptom rate with active ulcers, % 90 (50–90) 16
Recurrent symptom rate with healed ulcers, % 10 (0–30) 45
Recurrent symptom rate with no ulcer, %/y 30 (10–70) 56, 57
Ulcer recurrence withH. pylori infection, %/100 patient-months 2.7 (2.0–6.6) 22, 46–51
Ulcer recurrence with no infection, %/100 patient-months 0.6 (0.1–2.0) 52–55
Serious antibiotic complication per course,n 0.5 (0.1–1.0) 36, 39, 40
Sensitivity of qualitative serologic test forH. pylori, % 90 (50–1.00) 24, 25
Specificity of qualitative serologic test forH. pylori, % 95 (50–100) 24, 25
Sensitivity of upper GI radiography % 90 (22–91) 9–11
Specificity of upper GI radiography % 90 (90–99) 9–11
Sensitivity of rapid urease test % 90 (87–98) 26, 27




Rapid urease test $25
Antisecretory therapy (6-wk course at full dose) $17
Maintenance antisecretory therapy (per month) $11
Antibiotic course (includes adverse events) $250
Qualitative serologic test forH. pylori $20
Urea breath test $100
Physician office visit (primary care) $39
Physician office visit (GI) $80
Hospitalization for ulcer complication with no surgery $7,095
Hospitalization for ulcer complication with surgery $24,081
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upon third party expenditures. Payments, not charges, were
used to determine cost estimates. The national average of
charges allowed by the Health Care Financing Administra-
tion for Medicare reimbursement was used to determine the
lower bound of cost estimates, as the payment for similar
services varies between geographical regions and delivery
systems. The costs of antisecretory therapy (generic H2RA)
and HP eradication therapy were obtained from a University
hospital pharmacy. Indirect costs to the patient (lost pro-
ductivity, etc.) were not included in the analysis.
Sensitivity Analysis
Sensitivity analyses were used to assess the impact of vary-
ing clinical and cost inputs over a range reported in the
literature. Of note, we varied UGI cost, UGI performance
characteristics, and HP prevalence to determine the impact
these key variables on the cost-effectiveness of each
strategy.
RESULTS
Cost Per Ulcer Cured and Cost Per Patient Treated
In the base case analysis, the estimated treatment cost per
ulcer cured for each strategy were: test and treat $3025;
initial UGI $3690; and initial UGI with serology $3790 (Fig.
1). Each strategy led to an equivalent number of symptom-
atic ulcers cured because of the required endoscopic eval-
uations for patients with persistent symptoms. The model
predicted a lower average cost per patient treated for the test
Figure 1. Cost per ulcer cured by management strategy.
Figure 2. Cost per patient treated by management strategy.
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and treat strategy ($498) when compared to UGI ($610) and
UGI with serology ($620) (Fig. 2).
Sensitivity Analysis
COST OF UGI. The economic advantage of the test and
treat strategy relative to the UGI strategies was sensitive to
the cost of UGI. UGI becomes the preferred strategy in
terms of cost per patient treated as reimbursement for UGI
approached $50 (Fig. 3).
OPERATING CHARACTERISTICS OF UGI. We varied
the sensitivity and specificity of UGI to determine whether
there were a combination of performance characteristics at
which the UGI strategies would outperform the test and treat
strategy on economic grounds. Even when sensitivity and
specificity were estimated at 100%, the test and treat strat-
egy continued to yield a lower cost per ulcer cured when
compared to UGI strategies (test and treat, $3177; UGI
without serology $4192; and UGI with serology, $4363).
HP PREVALENCE. To approximate the evolving epide-
miology of HP, we varied the prevalence of HP infection in
the entire population while maintaining the proportion of
patients with PUD (20%) and HP-related PUD (90%). When
the HP prevalence in the population was as low as 20%, the
economic advantage of the test and treat approach persisted
compared to the UGI strategies (test and treat, $459; UGI
without serology, $623; and UGI with serology, $633).
We also assessed the impact of the decreased association
of HP with PUD (5). While maintaining the ulcer rate at
20% and population HP prevalence at 50%, we varied the
prevalence of HP-associated PUD from 9% to 90%. Again
test and treat strategy provided the lowest cost per patient
treated at all HP infection rates (at 9% prevalence, test and
treat, $485; UGI without serology, $575; and UGI with
serology, $592). When a worst-case scenario was assumed
(HP prevalence 20% and HP-associated PUD 60%), test and
treat had a lower cost per patient treated when compared to
the UGI strategies.
DISCUSSION
Over the last two decades, identification ofHelicobacter
pylori has revolutionized the diagnostic approach and treat-
ment of peptic ulcer disease. Simultaneously, cost contain-
ment and managed care initiatives have influenced access to
and reimbursement for diagnostic tests to document PUD. In
1985, the American College of Physicians (ACP) supported
an empiric approach with antisecretory agents to patients
with dyspepsia, reserving endoscopy for empiric treatment
failures (58). A recent position statement of the American
Gastroenterological Association supported a test and treat
strategy for those populations in which the prevalence of
infection is not universally high and gastric cancer is un-
common (2). In 1994 the NIH Consensus Panel recom-
mended documentation of HP infection in patients with a
diagnosis of PUD (either past or present) and subsequent
eradication (59). This implicitly embodied endoscopy as the
diagnostic test of choice as it would allow accurate and rapid
documentation of both diagnoses.
The economic impact of performing endoscopy on all
patients presenting with suspected peptic ulcer disease has
been previously examined (6, 7). Published decision anal-
Figure 3. Sensitivity analysis: cost of upper GI radiography.
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yses recommend a test and treat strategy over immediate
endoscopy at endoscopy costs greater than $500, as the
ulcer-related outcomes are similar at a decreased cost per
patient. In the test and treat strategy, endoscopy is reserved
for those who fail initial serology guided therapy, following
ACP guidelines. Randomized controlled trials are underway
to compare test and treat strategyversusimmediate endos-
copy.
Given the concerns regarding over-treatment of HP in
patients without PUD and unlikely to benefit from HP
eradication, initial diagnostic evaluation of patients with
UGI may be an attractive alternative because of low cost,
reasonable accuracy, and potential reassurance associated
with diagnostic testing. However, the value of diagnostic
tests in PUD and the reassurance they offer to patients is
unclear (60). A randomized controlled trial comparing UGI
versusempiric antisecretory therapy for patients with dys-
pepsia demonstrated that UGI did not confer a clinical
advantage nor did it impact on quality of life measures as
measured by the Sickness Impact Profile (61).
Our analyses reveal that test and treat provides similar
outcomes and an economic advantage over UGI strategies
even when we assumed UGI to be a perfect test for detection
of PUD. The cost-effective advantage of test and treat was
sensitive to the cost of invasive testing. If the cost of UGI
was less than $50, UGI would be preferred given similar
cost per patient treated, increased diagnostic accuracy, and
decreased unnecessary antibiotic use.
As the prevalence of HP infection decreases, increased
numbers of patients with false-positive serological tests
would receive inappropriate HP eradication therapy. This, in
turn, may lead to unnecessary antibiotic associated side
effects as well as the increased potential development of
antibiotic resistance. Although our model did not assess the
societal costs of antibiotic resistance, this consideration will
remain prominent, particularly as HP infection rates con-
tinue to decline and HP resistance to antibiotics rises (62,
63). However, even at the lowest boundaries of HP preva-
lence and HP associated PUD the economic advantage of
test and treat persisted. Alternatively, our model did not
include any benefit of HP eradication other than decreased
ulcer recurrence, such as potential reduced risk of gastric
carcinoma (64) or ulcer prevention in HP infected individ-
uals without active PUD (65). Inclusion of these potential
benefits would further enhance the argument for the test and
treat strategy.
In conclusion, for individuals with suspected PUD, the
test and treat strategy for HP is preferred when compared to
strategies that use UGI initially, at reimbursement rates
greater than $50. The recommendation to defer definitive
ulcer testing on initial presentation was not sensitive to
considerations of declining HP prevalence and decreased
association of HP to documented PUD. Regardless of initial
strategy chosen, it is important to note that endoscopy is
indicated in the presence of alarm symptoms and is war-
ranted in all patients with persistent symptoms after a single
course of therapy.
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